Market Strategy 2/22/2021
- February 22, 2021
Progress Not Perfection Remains the Order of the Day
Good news abounds on earnings and vaccines as investors mull the prospects of higher inflation
- Last week the number of vaccinations jumped higher across the world and in the US, increasing expectations of an economic recovery later this year.
- Retail sales jumped 5.3% in January fueled by stimulus payments that the Congress enacted in December— far exceeding expectations of economists who expected a 1.1% rise.
- Q4 earnings growth for the S&P 500 continued to exceed expectations through last week, adding justification for recent equity price gains.
- 10-year Treasury yields rose to 1.34% on Friday, up 42 basis points since the start of the year, on inflation fears that in our view may well be unfounded.
With almost 84% of the S&P500 companies having reported thus far in Q4 reporting season through last Friday, earnings are up 6.16% on the back of 2.69% revenue growth per Bloomberg data. Not too shabby we’d say, particularly as Barron’s reminded us this week that at the start of earnings season just weeks ago consensus had called for an 11% decline in earnings.
So far five of the 11 sectors in the broad market benchmark have posted double digit earnings growth for the period including: materials, consumer discretionary, financials, technology and health care. Two sectors have posted positive single digit growth (communications services and consumer staples) while two other sectors (utilities and real estate) have posted single digit negative earnings growth. The energy sector, reflecting the domestic and global impact of the pandemic over the course of the fourth quarter during which infections spiked in Europe and in the US, saw its member companies that have reported show losses steep enough so far in the season to list earnings growth as “not meaningful”.
Results thus far in Q4 earnings season underscore the resilience evidenced among many companies through the pandemic, suggesting that much of the broad market’s gains have been justified.
On the vaccine front progress is becoming genuinely visible towards stemming the spread of the virus as the logistical hurdles experienced in the initial rollouts stateside and elsewhere around the world are addressed. Bloomberg’s vaccine tracker this weekend showed that some 205 million shots have been given worldwide across 92 countries. In the US nearly 65 million inoculations have been given so far.
In our experience the bond market has been known to project its expectations for inflation well beyond levels that are justified by the trends in the actual inflation rate.
Even as signs of progress against the pandemic rise in prominence, “what if” worries abound around the potential for virus variants to elude the current vaccines. Prominent vaccine developers and manufacturers appear confident that the existing vaccines or future variations on the vaccines will likely provide protection against mutant strains. We are reminded once again that wherever there is opportunity risk likely lies near and that wherever there is risk opportunity likely lies near. So far the efficacy of the most prominent vaccines being distributed around the world has raised confidence and improved sentiment at both the consumer and business levels worldwide. In our view, so far so good. Time ultimately will be the judge.
Investors Begin to Contemplate a Post Pandemic World
As the commodities markets, bond markets and the stock markets begin to discount the potential global economic recovery that likely lies ahead as Covid-19 and its variant kin get pushed into the rearview mirror worries about how much inflation the process of reflating the US and global economy might generate have grown.
Keeping the volatility typically inherent in the commodities markets as well as the potential for nervousness often found in the bond market in context appears to us to be the best course to follow at this time. Currently markets are navigating the transition from economies held hostage by the pandemic towards a process of economic revovery—eventally leading to sustainable expansions on a global basis. Such process will likely bring periods of resurgence and outsized growth that may represent economic reflation rather than prospects of untoward high inflation.
We counter the worries we hear about risks of levels of inflation high enough to cause the Federal Reserve (or other major central banks around the developed and emerging world) to “slam on the brakes” as unlikely due to long established vigilance by monetary authorities against inflation as well as secular trends tied to technology and globalization that are counter-inflationary. The latter include robotics on the factory floor, algorithms in the offices, the globalization of the labor force, strong competition among businesses, overcapacity within many sectors worldwide and an abundance of capacity to discover, process and deliver commodities worldwide (notwithstanding current bottlenecks caused in the short term by disruption to supply chains from by the pandemic).
Near-term Treasury bond prices are likely to remain under pressure as yields rise in anticipation of the economic re-openings that lie ahead. That said, in our experience the bond market has been known to project its expectations for inflation well beyond levels that are justified by the trends in the actual inflation rate.
As recently as 2018 the bond market over projected where bond yields were likely to normalize. Remember the 10-year Treasury at 3.11% in May of that year or its yield at 3.24% in November? Weeks later the price of the 10-year Treasury rallied to close the year at 2.69%, apparently on the realization that such a high yield represented how attractive it was to bond buyers rather than how far yields had further to go higher. The 10-year has not had a yield of 3% since 2018.
Looking back further in modern market history consider 1994 through the first quarter of 1995: a period wherein the Federal Reserve had raised rates convincing many market participants that rates would continue to rise through 1995. Yet it didn’t happen.
Once again time will tell. For now we’ll favor equities over fixed income, remain overweight US markets while maintaining meaningful exposure to international developed and emerging markets. Among the sectors of the S&P 500 we rate as outperform are: information technology, consumer discretionary, financials and industrials.
Related to market capitalizations we are near market cap agnostic finding opportunity among large, mid, and small equity capitalizations. In terms of style we opt to own a mix of growth and value companies as investor appetite broadens for equities and as the global economy moves towards economic recovery.
Chief Investment Strategist, Oppenheimer Asset Management Inc.
John is one of the most popular faces around Oppenheimer: our clients have come to rely on his market recaps for timely analysis and a confident viewpoint on the road forward. He frequently lends his expertise to CNBC, Bloomberg, Fox Business, and other notable networks.
Additional Market Insights
This report is issued and approved by Oppenheimer & Co. Inc., a member of all Principal Exchanges, and SIPC. This report is distributed by Oppenheimer & Co. Inc., for informational purposes only, to its institutional and retail investor clients. This report does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited. The securities mentioned in this report may not be suitable for all types of investors. This report does not take into account the investment objectives, financial situation or specific needs of any particular client of Oppenheimer & Co. Inc. Recipients should consider this report as only a single factor in making an investment decision and should not rely solely on investment recommendations contained herein, if any, as a substitution for the exercise of independent judgment of the merits and risks of investments. The strategist writing this report is not a person or company with actual, implied or apparent authority to act on behalf of any issuer mentioned in the report. Before making an investment decision with respect to any security discussed in this report, the recipient should consider whether such investment is appropriate given the recipient's particular investment needs, objectives and financial circumstances. We recommend that investors independently evaluate particular investments and strategies, and encourage investors to seek the advice of a financial advisor. Oppenheimer & Co. Inc. will not treat non-client recipients as its clients solely by virtue of their receiving this report. Past performance is not a guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance of any security mentioned in this report. The price of the securities mentioned in this report and the income they produce may fluctuate and/or be adversely affected by exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal.
Oppenheimer & Co. Inc. accepts no liability for any loss arising from the use of information contained in this report. All information, opinions and statistical data contained in this report were obtained or derived from public sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such information, opinion or statistical data is accurate or complete and they should not be relied upon as such. All estimates and opinions expressed herein constitute judgments as of the date of this report and are subject to change without notice. Nothing in this report constitutes legal, accounting or tax advice. Since the levels and bases of taxation can change, any reference in this report to the impact of taxation.
Investment Strategy should not be construed as offering tax advice on the tax consequences of investments. As with any investment having potential tax implications, clients should consult with their own independent tax adviser.
This report may provide addresses of, or contain hyperlinks to, Internet web sites. Oppenheimer & Co. Inc. has not reviewed the linked Internet web site of any third party and takes no responsibility for the contents thereof. Each such address or hyperlink is provided solely for the recipient's convenience and information, and the content of linked third party web sites is not in any way incorporated into this document. Recipients who choose to access such third-party web sites or follow such hyperlinks do so at their own risk. The S&P 500 Index is an unmanaged value-weighted index of 500 common stocks that is generally considered representative of the U.S. stock market. The S&P 500 index figures do not reflect any fees, expenses or taxes. This research is distributed in the UK and elsewhere throughout Europe, as third party research by Oppenheimer Europe Ltd, which is authorized and regulated by the Financial Conduct Authority (FCA). This research is for information purposes only and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This report is for distribution only to persons who are eligible counterparties or professional clients and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the UK only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) High Net Worth companies, unincorporated associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. In particular, this material is not for distribution to, and should not be relied upon by, retail clients, as defined under the rules of the FCA. Neither the FCA’s protection rules nor compensation scheme may be applied. This report or any portion hereof may not be reprinted, sold, or redistributed without the written consent of Oppenheimer & Co. Inc. Copyright © Oppenheimer & Co. Inc. 2020.